ArticleMicrobiome2022
A comprehensive evaluation of microbial differential abundance analysis methods: current status and potential solutions.
Article in Microbiome, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07007169 (Mediterranean Diet and Inequality in Early Breast Cancer), which is not on this map. Cited by 120 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mediterranean Diet and Inequality in Early Breast Cancer: A Multicenter Randomized Clinical Trial
Who cites it
120 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pancreatic microbiota composition and diversity in pancreatitis-associated infection: a systematic review with focus on infected pancreatic necrosis.Frontiers in microbiology · 2026Pooled it
- Meta-analysis of gut microbiome reveals patterns of dysbiosis in colorectal cancer patients.Journal of medical microbiology · 2025Pooled it
- Cross-cohort analysis identifies shared gut microbial signatures and validates microbial risk scores for colorectal cancer.Journal of translational medicine · 2025Pooled it
- Clinical Trial: Multi-Strain Probiotic Improves Bile Acid Profile, Microbiome, and Metabolomic Parameters in Patients With History of Bile Acid Malabsorption-A Randomized, Controlled Trial.Alimentary pharmacology & therapeutics · 2026Trial
- Gut Colonization With Vancomycin-Resistant Enterococcus Shapes the Gut Microbiome in the Intensive Care Unit.The Journal of infectious diseases · 2025Trial
- The phageome of patients with ulcerative colitis treated with donor fecal microbiota reveals markers associated with disease remission.Nature communications · 2024Trial
- Article
- Compositional and functional differences of gut microbiome and metabolome inform pathogenesis of cholestatic liver disease.Gut microbes · 2026Article
- From gut to brain: data-driven evidence suggests causal contribution of gut-microbiota to major depressive disorder in humans.Gut microbes · 2026Article
- Not all stress is equal: Examination stress and cortisol reactivity are associated with exploratory species-level variation but not broad restructuring of the gut microbiome.Neurobiology of stress · 2026Article
- Profiling Gut Microbiome and Metabolites Aids Diagnosis and Prediction of Progression in Mild Cognitive Impairment.MedComm · 2026Article
- A joint mixture Tobit method with latent microbial abundance improves detection of microbiome-disease associations in zero-inflated data.PLoS computational biology · 2026Article
- Endoscopic Application of GM-CSF, Fosfomycin, and Metronidazole in Pouchitis, a Phase I Safety and Pilot Study.Digestive diseases and sciences · 2026Article
- IRS: iterative reference selection improves normalization of microbiome sequencing data.Briefings in bioinformatics · 2026Article
- Not every gene is special: Modelling scale controls the false discovery rate when analysing high-throughput sequencing data.PLoS computational biology · 2026Article
- Body mass index-associated gut microbial taxa and functional pathways in women with benign and malignant breast disease.Breast cancer research and treatment · 2026Article
- From diversity to dominance: how salt and CO₂ shape LAB-dominated ecosystems in vegetable fermentations.Microbiology spectrum · 2026Article
- Distinct gut microbiome profiles characterize obese and non-obese patients with atherosclerosis: a metagenomic analysis.Journal of translational medicine · 2026Article
- Trending ileal microbiome dysbiosis over time as an early assessment of intestinal transplant rejection risk.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundDifferential abundance analysis (DAA) is one central statistical task in microbiome data analysis. A robust and powerful DAA tool can help identify highly confident microbial candidates for further biological validation. Numerous DAA tools have been proposed in the past decade addressing the special characteristics of microbiome data such as zero inflation and compositional effects. Disturbingly, different DAA tools could sometimes produce quite discordant results, opening to the possibility of cherry-picking the tool in favor of one's own hypothesis. To recommend the best DAA tool or practice to the field, a comprehensive evaluation, which covers as many biologically relevant scenarios as possible, is critically needed.
resultsWe performed by far the most comprehensive evaluation of existing DAA tools using real data-based simulations. We found that DAA methods explicitly addressing compositional effects such as ANCOM-BC, Aldex2, metagenomeSeq (fitFeatureModel), and DACOMP did have improved performance in false-positive control. But they are still not optimal: type 1 error inflation or low statistical power has been observed in many settings. The recent LDM method generally had the best power, but its false-positive control in the presence of strong compositional effects was not satisfactory. Overall, none of the evaluated methods is simultaneously robust, powerful, and flexible, which makes the selection of the best DAA tool difficult. To meet the analysis needs, we designed an optimized procedure, ZicoSeq, drawing on the strength of the existing DAA methods. We show that ZicoSeq generally controlled for false positives across settings, and the power was among the highest. Application of DAA methods to a large collection of real datasets revealed a similar pattern observed in simulation studies.
conclusionsBased on the benchmarking study, we conclude that none of the existing DAA methods evaluated can be applied blindly to any real microbiome dataset. The applicability of an existing DAA method depends on specific settings, which are usually unknown a priori. To circumvent the difficulty of selecting the best DAA tool in practice, we design ZicoSeq, which addresses the major challenges in DAA and remedies the drawbacks of existing DAA methods. ZicoSeq can be applied to microbiome datasets from diverse settings and is a useful DAA tool for robust microbiome biomarker discovery. Video Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.